Incidence of POI-related postoperative morbidity ( postoperative nasogastric tube insertion or POI-related prolonged hospital stay or readmission ) was analyzed in four North American trials for placebo or alvimopan 12 mg administered 30 minutes or more preoperatively and twice daily postoperatively until hospital discharge ( 7 or fewer postoperative days ) .
